Enabling the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants including KP.2

Bibliographic Details
Title: Enabling the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants including KP.2
Authors: Chao Su, Juanhua He, Yufeng Xie, Yu Hu, Xin Li, Shitong Qiao, Peipei Liu, Min Huang, Rong Zhang, Liang Wang, Zhen Chang, Wenqiao Sun, Ke Xu, Jing Zhang, Longxing Cao, Pengcheng Han, Xin Zhao, Jianxun Qi, Qihui Wang, Mengsu Yang, George Fu Gao
Source: hLife, Vol 3, Iss 3, Pp 132-145 (2025)
Publisher Information: Elsevier, 2025.
Publication Year: 2025
Collection: LCC:Medicine
Subject Terms: etesevimab (CB6), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), receptor-binding domain (RBD), broad-spectrum and affinity-mature antibody design (BAADesign), antibody, Medicine
More Details: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously evolving since 2019. Some monoclonal antibodies (mAbs) have been developed and widely used, such as etesevimab (CB6) developed by Eli-Lilly/Junshi. However, the mAb escaped from the variant of concern (VOC) ever since the emergence of Beta VOC, with a complete loss of efficacy against the Omicron subvariants. Here, we developed a broad-spectrum and affinity-mature antibody design (BAADesign) procedure to design CB6, enabling it to bind to the receptor-binding domains (RBDs) of multiple important Omicron subvariants, including the recent variant KP.2. Structural analysis confirmed the desired CB6-RBD interactions. Additionally, identical mutations in the complementarity determining regions (CDR)1 and CDR2 of the CB6 mutants also restored neutralizing potency for some RBD-1 group antibodies. Overall, the enhanced CB6 neutralizing capacity makes it a promising candidate against SARS-CoV-2 infection, and the BAADesign method has implications for the design of other antibodies.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2949-9283
14847469
Relation: http://www.sciencedirect.com/science/article/pii/S294992832400107X; https://doaj.org/toc/2949-9283
DOI: 10.1016/j.hlife.2024.12.006
Access URL: https://doaj.org/article/d643a08bf14847469fb22e0a847dcdd6
Accession Number: edsdoj.643a08bf14847469fb22e0a847dcdd6
Database: Directory of Open Access Journals
More Details
ISSN:29499283
14847469
DOI:10.1016/j.hlife.2024.12.006
Published in:hLife
Language:English